Biomedical Engineering Reference
In-Depth Information
Table 7.4
(
Continued
)
Treatment
(# pts in
trial/# pts
with marker
analysis)
N (%)
on
treatment
arms
Method
of
KRAS
testing
KRAS
status
Study
mPFS
OS
ORR (%)
PRIME Douillard J
et al.
Panitumumab
and FOLFOX
vs. FOLFOX
Allele
specific real
time PCR
WT
325 vs. 331
9.6 vs. 8.0 mo (HR
= 0.80,
23.9 vs. 19.7
mo
(HR = 0.83,
55 vs. 48
, 2010
P
= 0.02)
[36]
P
= 0.72)
MT
221 vs. 219
7.3 vs. 8.8 mo
(HR = 1.29;
15.5 vs. 19.3
mo
(HR = 1.24,
40 vs. 40
P
=
0.02)
P
= 0.07)
Peeters M
et al.,
Panitumumab
+ FOLFIRI vs.
FOLFIRI
Allele
specific real
time PCR
WT
303 vs. 294
5.9 vs. 3.9 mo
(HR = 0.73,
14.5 vs. 12.5
mo (HR =
0.85,
35 vs. 10
2010
[37]
P
=
0.004)
P
= 0.12)
MT
238 vs. 248
5.0 vs. 4.0
(HR_0.85;
11.8 vs. 11.1
mo
(HR = 0.94)
13 vs. 14
P
=
0.14)
